NasdaqGS - Delayed Quote USD

Vir Biotechnology, Inc. (VIR)

8.23 +0.60 (+7.86%)
At close: April 26 at 4:00 PM EDT
8.22 -0.01 (-0.12%)
After hours: April 26 at 6:34 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. CEO & Director 4.47M -- 1969
Mr. Sung H. Lee Executive VP & CFO 968.45k -- 1970
Dr. Ann M. Hanly Ph.D. Executive VP & Chief Technology Officer 896.07k -- 1970
Dr. Jeff Calcagno M.D. Executive VP & Chief Business Officer 860.49k -- 1961
Dr. Klaus Frueh Ph.D. Co-Founder & Scientific Advisor 177.66k -- 1960
Dr. Lawrence Corey M.D. Co-Founder & Scientific Advisor -- -- 1948
Dr. Louis J. Picker M.D. Co-Founder & Scientific Advisor -- -- --
Dr. Jennifer Eileen Towne Ph.D. Executive VP & Chief Scientific Officer -- -- --
Ms. Heather Rowe Armstrong Vice President of Investor Relations -- -- --
Ms. Vanina De Verneuil J.D. Executive VP, General Counsel & Corporate Secretary -- -- --

Vir Biotechnology, Inc.

1800 Owens Street
Suite 900
San Francisco, CA 94158
United States
415 906 4324 https://www.vir.bio
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
587

Description

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Corporate Governance

Vir Biotechnology, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 6; Board: 4; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 02, 2024
Vir Biotechnology, Inc. Earnings Call

Related Tickers

SAGE Sage Therapeutics, Inc.
13.69
+0.81%
 
ALLO Allogene Therapeutics, Inc.
2.8900
+1.23%
 
RLAY Relay Therapeutics, Inc.
6.37
+3.49%
 
CVAC CureVac N.V.
2.3300
+0.87%
 
BLUE bluebird bio, Inc.
0.9228
+1.13%
 
CYTK Cytokinetics, Incorporated
65.34
+0.83%
 
VERV Verve Therapeutics, Inc.
6.16
-0.96%
 
ALNY Alnylam Pharmaceuticals, Inc.
143.31
-0.28%
 
ALEC Alector, Inc.
5.25
+9.15%
 
BMRN BioMarin Pharmaceutical Inc.
80.91
-1.53%